Published: 3 April 2022
Author(s): Marieke de Vries, Fatima El-Morabit, Karel J. van Erpecum, Jan Westerink, Simon T. Bac, H.A.H. (Karin) Kaasjager, Harold W. de Valk
Issue: June 2022
Section: Original article

Alongside the obesity-epidemic, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide, with an estimated prevalence of 25% in the general population [1]. NAFLD is a spectrum of liver disease, encompassing isolated hepatic steatosis (HS) and non-alcoholic steatohepatitis, which may progress to fibrosis, cirrhosis and hepatocellular carcinoma. NAFLD has a high clinical and economic burden, as it is currently the most common indication for liver transplantation, comes with an increased risk of hepatocellular carcinoma, and is associated with cardiovascular disease, and mortality [1,2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.